📊 JANX Key Takeaways
Is JANX a Good Investment? Thesis Analysis
Janux Therapeutics is a pre-revenue biotech company with severe cash burn (-$82.2M operating cash flow) and only $52.3M in cash reserves, implying a runway of approximately 6-8 months at current burn rates. The company is deeply unprofitable (-$113.6M net loss) with negative margins exceeding -1000%, characteristic of a clinical-stage pharmaceutical firm with no commercialized products and no clear path to profitability in the near term.
Why Buy JANX? Key Strengths
- Strong balance sheet with minimal debt ($0M long-term debt) and low leverage (0.00x D/E ratio)
- Excellent liquidity position with 39.04x current ratio, providing operational flexibility
- Substantial equity cushion of $956.8M providing strategic flexibility for R&D and potential partnerships
JANX Investment Risks to Consider
- Severe cash burn rate of $82.2M annually against only $52.3M in cash equivalents indicates imminent need for capital raise or strategic action
- No revenue generation with only $10.0M reported (likely from grants/milestone payments) insufficient to offset operating losses
- Critical funding risk: current cash runway of 6-8 months at observed burn rates creates existential liquidity pressure and risk of equity dilution
- Operating and net margins of -1576.7% and -1136.2% respectively reflect highly unprofitable pre-commercial operations typical of high-risk biotech
Key Metrics to Watch
- Cash and equivalents balance and runway (critical near-term survival metric)
- Quarterly operating cash burn rate and trajectory
- Clinical trial progress and regulatory milestones for pipeline programs
- Capital raise announcements and terms (equity dilution risk)
- R&D spending efficiency and pipeline advancement
JANX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 39.04x current ratio provides a solid financial cushion.
JANX Profitability Ratios
JANX vs Healthcare Sector
How Janux Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JANX Overvalued or Undervalued?
Based on fundamental analysis, Janux Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JANX Balance Sheet & Liquidity
JANX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Janux Therapeutics, Inc.'s revenue has grown significantly by 191% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
JANX Growth Metrics (YoY)
JANX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $439.0K | -$24.3M | $-0.39 |
| Q2 2025 | N/A | -$6.0M | $-0.11 |
| Q1 2025 | N/A | -$14.8M | $-0.30 |
| Q3 2024 | $439.0K | -$11.6M | $-0.25 |
| Q2 2024 | $1.1M | -$6.0M | $-0.11 |
| Q1 2024 | $1.3M | -$14.8M | $-0.30 |
| Q3 2023 | $1.8M | -$11.6M | $-0.25 |
| Q2 2023 | $1.1M | -$16.9M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
JANX Capital Allocation
JANX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Janux Therapeutics, Inc. (CIK: 0001817713)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JANX
What is the AI rating for JANX?
Janux Therapeutics, Inc. (JANX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are JANX's key strengths?
Claude: Strong balance sheet with minimal debt ($0M long-term debt) and low leverage (0.00x D/E ratio). Excellent liquidity position with 39.04x current ratio, providing operational flexibility.
What are the risks of investing in JANX?
Claude: Severe cash burn rate of $82.2M annually against only $52.3M in cash equivalents indicates imminent need for capital raise or strategic action. No revenue generation with only $10.0M reported (likely from grants/milestone payments) insufficient to offset operating losses.
What is JANX's revenue and growth?
Janux Therapeutics, Inc. reported revenue of $10.0M.
Does JANX pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
Where can I find JANX SEC filings?
Official SEC filings for Janux Therapeutics, Inc. (CIK: 0001817713) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JANX's EPS?
Janux Therapeutics, Inc. has a diluted EPS of $-1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JANX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Janux Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JANX stock overvalued or undervalued?
Valuation metrics for JANX: ROE of -11.9% (sector avg: 15%), net margin of -1,136.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JANX stock in 2026?
Our dual AI analysis gives Janux Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JANX's free cash flow?
Janux Therapeutics, Inc.'s operating cash flow is $-82.2M, with capital expenditures of $1.0M. FCF margin is -832.8%.
How does JANX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,136.3% (avg: 12%), ROE -11.9% (avg: 15%), current ratio 39.04 (avg: 2).